Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

SAN DIEGO, April 15, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a new analysis of an ongoing, long-term research study of the investigational drug metreleptin, an analog of the human hormone leptin, for the treatment of lipodystrophy. The study is being conducted by investigators from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). Results from the analysis will be presented by Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals, at a late-breaking oral session on Sunday, April 17 at 7:55 a.m. PT at the 20th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists (AACE) in San Diego.

In the study, which has been ongoing for more than 10 years, researchers at the NIH are examining the effect of metreleptin on several metabolic abnormalities, including diabetes and hypertriglyceridemia (high levels of triglycerides in the bloodstream), in patients with rare inherited or acquired forms of lipodystrophy. Treatment with metreleptin resulted in robust reductions from baseline in both A1C and triglycerides. (A1C is a measure of average blood sugar over three months; triglycerides are the major form of fat stored in the body.) These improvements were apparent at four months and generally sustained for up to several years of treatment.

"Patients with rare forms of lipodystrophy are often affected by the disease early in life, are at high risk of acute and chronic complications and, currently, have very limited therapeutic options," said Dr. Weyer. "The results of our analysis reaffirm the potential of metreleptin as an important advance for people living with this chronic and often debilitating metabolic disease. We continue to work diligently toward bringing this potential
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/zkkg9q/blood_processing ) has announced ... - Global Strategic Business Report" report to their offering. ... US, Canada , Japan ... , Latin America , and Rest of ... 2014 through 2020. Also, a seven-year historic analysis is provided ...
(Date:6/2/2015)... DUBLIN , June 02, 2015 Research and ... "Surgical Incision Closures - Global Strategic Business Report" ... comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America ... the worldwide markets for Surgical Incision Closures in US$ Million ...
(Date:6/2/2015)... , June 2, 2015 Intarcia Therapeutics, ... $75 million from its recently announced synthetic royalty / ... $300 million. Investors have purchased Convertible Limited Recourse Notes ... equal to 2.0% of any future global net sales ... fully paid. Investors also have the option, commencing upon ...
Breaking Medicine Technology:Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 2Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 3Surgical Incision Closures - Global Strategic Business Report 2015 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 3
(Date:6/2/2015)... Long Island, N.Y. (PRWEB) June 02, 2015 ... to refer to computer generated imagery overlaid on the ... and gone but Vein Visualization, which displays a map ... has shown a steady growth in adoption. , AccuVein, ... a 40% year over year growth rate and such ...
(Date:6/2/2015)... “ Radaris ” was featured on NewsWatch as part ... latest and coolest applications on the market for iOS, Android, ... expert, conducted the app review and shared with viewers can ... person. , According to Psychology Today, humans are a curious ... that curiosity is a part of human development. People are ...
(Date:6/2/2015)... FL (PRWEB) June 02, 2015 MedPro ... staffing services to healthcare facilities, today announced the worldwide ... and effective mobile tool to help candidates find best ... Glassdoor survey released in 2014, 9 in 10 job ... during their job search. , The MedPro Top Jobs ...
(Date:6/2/2015)... OR (PRWEB) June 02, 2015 ZOOM+, ... of ZOOM+ Performance Health Insurance, announced today the opening ... Clean White 57 - a three-in-one complete dental exam, ... Clean Jr. for kids. Like all ZOOM+ services, ZOOM+Smile ... , “Why shouldn’t the dentist office be as inviting ...
(Date:6/2/2015)... DiaTech Oncology, provider of CorrectChemo®, the ... help oncologists provide personalized cancer treatment, has gained ... for its laboratories in the U.S. and Canada. ... the ‘Good Housekeeping’ seal of approval,” says Robert ... DiaTech. “It’s a rigorous inspection that confirms our ...
Breaking Medicine News(10 mins):Health News:Vein Visualization Emerges as Premier Augmented Reality Application 2Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2Health News:MedPro Healthcare Staffing Launches New MedPro Top Jobs App To Facilitate Job Search For Healthcare Professionals 2Health News:ZOOM+ Opens Its First On-Demand ZOOM+Smile Studio and Reinvents the Dental Exam 2Health News:DiaTech Oncology Gains College of American Pathologists Accreditation for U.S. CorrectChemo Laboratory 2
... the University of Wisconsin-Madison have identified dozens of clues ... ,The researchers identified nearly 40 genes that, ... the parasite from forming an infection in the brains ... of promising targets for developing drugs that could block ...
... brand ambassadors of India. But they could also prove a ... case of Thirumurthy Nakka Boomaiah , 35 and hailing ... ,He has been sentenced to 69 days in ... London to Philadelphia and assaulting flight attendants. But he has ...
... Michigan patients will have a new -- virtually pain ... Joseph Mercy Health System (SJMHS) announced today it will ... System on Wednesday, June 6th. ,This advanced ... body, including previously inoperable tumors, with astounding accuracy and ...
... The Seattle-based Infectious Disease Research Institute (IDRI) and ... entered into two research and development agreements ... Leishmaniasis and Leprosy, two 'neglected diseases' targeted by ... using Chembio's patented Dual Path immunoassay test platform ...
... blockbuster drug and greater reimbursement levels for the treatment ... smoking cessation and addiction treatments are expected to ... 2005 to more than $2.3 billion in 2010, according ... Analysis, a new study released today from Kalorama Information. ...
... A psychologist at the University College London has designed a ... can be distracted. ,Professor Nilli Lavie claims that ... tool during the recruitment process, and may be beneficial in ... ,"When you are easily distracted, you are more liable ...
Cached Medicine News:Health News:Mutant Parasites, Unable to Infect Hosts, Highlight Virulence Genes 2Health News:Indian Engineer Sentenced for Groping Women During Flight 2Health News:Advanced Cancer Treatment Brings New Hope to Michigan Patient 2Health News:IDRI and Chembio to Develop Tests for Leishmaniasis and Leprosy 2Health News:IDRI and Chembio to Develop Tests for Leishmaniasis and Leprosy 3Health News:Individuals Distraction can Be Measured by a Computer Based Test 2
... Wireless, internet-based ... provides compliance and ... complete system. The ... System incorporates communication ...
GelPort hand access laparoscopy combines the patient outcomes of minimally invasive surgery with the speed and precision of open surgery....
The CPAP TREND 110 delivers performance with quiet operation. Can be used together with the SomnoPlus CPAP Mask and AquaTrend Heated Humidifier....
... The SleepStyle 200 series offers ... integrated CPAP models. The design delivers ... patients. Performance features promote results in ... care. The strongest differentiator in the ...
Medicine Products: